Novartis (NVS) is facing a "sharp deceleration" in growth in mid-2025 amid patent expiries and limited newsflow levers, UBS Securities said in a Wednesday note.
According to UBS, Novartis' 2025 guidance "illustrates" headwinds from mid-year, with earnings before interest and taxes to grow by high teens in H1 and then slow to low to mid-single digits in H2.
Novartis enters a period of patent expiries and has limited pipeline readouts this year, but its in-market portfolio still has the potential to deliver on the company's mid-term growth targets, UBS said.
UBS downgraded the stock to neutral from buy.
NVS shares were 0.8% higher in recent trading.
Price: 107.89, Change: +0.89, Percent Change: +0.83
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。